A significant legal challenge has been resolved in favor of Abbott Laboratories. This week, a U.S. federal court issued a final dismissal of a class-action lawsuit alleging data privacy violations, providing a favorable outcome for the healthcare giant. The company, which processes sensitive patient information through its digital health monitors, successfully defended itself against the claims. In a separate development, several of the firm’s executives, including CEO Robert B. Ford, engaged in stock sales.
Court Dismisses Privacy Allegations with Prejudice
The U.S. District Court for the Northern District of Illinois ruled on Monday to dismiss the case against Abbott. Plaintiffs had accused the corporation of sharing protected consumer health data with technology platforms such as Meta and Google, alleging breaches of both state and federal privacy regulations. In his decision, the presiding judge found that the claimants failed to provide sufficient evidence to substantiate their allegations. The court rejected the negligence claims as well as the asserted violations of the Electronic Communications Privacy Act. The dismissal carries prejudice, preventing the lawsuit from being refiled.
This ruling represents a crucial development for Abbott. The handling of health data from connected medical devices is a complex regulatory area, making the definitive dismissal a source of legal clarity. The decision also removes a potential financial liability for the company.
Should investors sell immediately? Or is it worth buying Abbott Laboratories?
Executive Stock Transactions Filed
Concurrently, regulatory filings revealed share disposals by multiple Abbott executives. On March 2, three senior figures sold holdings on the open market. Senior Vice President Eric Shroff disposed of 709 shares, Executive Vice President Elizabeth Cushman sold 263 shares, and Vice President John A. McCoy Jr. parted with 585 shares. These transactions were executed at an average price of $115.58 per share.
Separately, CEO Robert B. Ford relinquished 30,308 shares on February 27. This transaction was not a market sale but rather a transfer to cover tax obligations, executed at a price of $116.26 per share. Following this move, Ford retains direct ownership of 306,461 shares. On the same date, John A. McCoy also utilized 1,142 shares for tax-related purposes.
Such sales are considered routine following the vesting of equity awards and are primarily conducted to satisfy tax liabilities. The transactions do not appear to follow a pattern that would indicate a shift in the executives’ outlook for the company.
Ad
Abbott Laboratories Stock: Buy or Sell?! New Abbott Laboratories Analysis from March 4 delivers the answer:
The latest Abbott Laboratories figures speak for themselves: Urgent action needed for Abbott Laboratories investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 4.
Abbott Laboratories: Buy or sell? Read more here...










